Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 11
Submit an article Journal homepage
268
Views
13
CrossRef citations to date
0
Altmetric
Review

Recent progress in canine tumor vaccination: potential applications for human tumor vaccines

Sofie Denies Laboratory of Gene Therapy, Department of Nutrition, Genetics and Ethology, Faculty of Veterinary Medicine, Ghent University, Heidestraat 19, B-9820 Merelbeke, Belgium
&
Niek N Sanders Laboratory of Gene Therapy, Department of Nutrition, Genetics and Ethology, Faculty of Veterinary Medicine, Ghent University, Heidestraat 19, B-9820 Merelbeke, Belgium. [email protected]
Pages 1375-1386 | Published online: 09 Jan 2014

References

  • Swann JB, Smyth MJ. Immune surveillance of tumors. J. Clin. Invest. 117(5), 1137–1146 (2007).
  • Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 18(8), 781–792 (2000).
  • Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy – revisited. Nat. Rev. Drug Discov. 10(8), 591–600 (2011).
  • Di LG, Ferro M, Buonerba C. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU Int. 110, E99–E104 (2011).
  • Grosenbaugh DA, Leard AT, Bergman PJ et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am. J. Vet. Res. 72(12), 1631–1638 (2011).
  • Jain KK. Personalized cancer vaccines. Expert Opin. Biol. Ther. 10(12), 1637–1647 (2010).
  • Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol. Immunother. 60(8), 1161–1171 (2011).
  • Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 241(1), 104–118 (2011).
  • Srinivasan R, Wolchok JD. Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J. Transl. Med. 2(1), 12 (2004).
  • Wolchok JD, Yuan J, Houghton AN et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol. Ther. 15(11), 2044–2050 (2007).
  • Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother. 58(3), 317–324 (2009).
  • Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin. Vaccine Immunol. 18(1), 23–34 (2011).
  • Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100(11), 2014–2021 (2009).
  • Cheng YH, Wong EW, Cheng CY. Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis 1(3), 209–220 (2011).
  • Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol. Lett. 115(1), 33–42 (2008).
  • Pinho SS, Carvalho S, Cabral J, Reis CA, Gärtner F. Canine tumors: a spontaneous animal model of human carcinogenesis. Transl. Res. 159(3), 165–172 (2012).
  • Pang LY, Argyle DJ. Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim. Biophys. Acta 1792(4), 380–391 (2009).
  • Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S. Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatr. Blood Cancer 58(3), 327–333 (2012).
  • Khanna C, London C, Vail D, Mazcko C, Hirschfeld S. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin. Cancer Res. 15(18), 5671–5677 (2009).
  • Finocchiaro LM, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Ther. 15(4), 267–276 (2008).
  • Finocchiaro LM, Villaverde MS, Gil-Cardeza ML, Riveros MD, Glikin GC. Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas. Res. Vet. Sci. 91(2), 230–234 (2011).
  • Sorenmo KU, Krick E, Coughlin CM et al. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin’s lymphoma. PLoS One 6(8), e24167 (2011).
  • Turek MM, Thamm DH, Mitzey A et al. Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma. Vet. Comp. Oncol. 5(4), 219–231 (2007).
  • Gyorffy S, Rodriguez-Lecompte JC, Woods JP et al. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J. Vet. Intern. Med. 19(1), 56–63 (2005).
  • Mito K, Sugiura K, Ueda K et al. IFN{γ} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models. Cancer Res. 70(18), 7093–7101 (2010).
  • Henson MS, Curtsinger JM, Larson VS et al. Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma. Vet. Comp. Oncol. 9(2), 95–105 (2011).
  • Peruzzi D, Gavazza A, Mesiti G et al. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol. Ther. 18(8), 1559–1567 (2010).
  • Thacker EE, Nakayama M, Smith BF et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 27(50), 7116–7124 (2009).
  • Hangalapura BN, Timares L, Oosterhoff D, Scheper RJ, Curiel DT, de Gruijl TD. CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic. J. Gene Med. 14(6), 416–427 (2012).
  • MacEwen EG, Kurzman ID, Vail DM et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 5(12), 4249–4258 (1999).
  • MacEwen EG, Kurzman ID, Rosenthal RC et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl Cancer Inst. 81(12), 935–938 (1989).
  • Meyers PA, Schwartz CL, Krailo MD et al.; Children’s Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J. Clin. Oncol. 26(4), 633–638 (2008).
  • Goubier A, Fuhrmann L, Forest L et al. Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFN gamma T cell responses in the dog. Vaccine 26(18), 2186–2190 (2008).
  • Peruzzi D, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 28(5), 1201–1208 (2010).
  • Tamura K, Arai H, Ueno E et al. Comparison of dendritic cell-mediated immune responses among canine malignant cells. J. Vet. Med. Sci. 69(9), 925–930 (2007).
  • Tamura K, Yamada M, Isotani M et al. Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells. Vet. J. 175(1), 126–129 (2008).
  • Bird RC, Deinnocentes P, Lenz S, Thacker EE, Curiel DT, Smith BF. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. Vet. Immunol. Immunopathol. 123(3–4), 289–304 (2008).
  • Bird RC, Deinnocentes P, Church Bird AE, van Ginkel FW, Lindquist J, Smith BF. An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine. Cancer Immunol. Immunother. 60(1), 87–97 (2011).
  • Milner RJ, Salute M, Crawford C, Abbot JR, Farese J. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine. Vet. Immunol. Immunopathol. 114(3–4), 273–284 (2006).
  • Hogge GS, Burkholder JK, Culp J et al. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther. 6(1), 26–36 (1999).
  • Smith BF, Baker HJ, Curiel DT, Jiang W, Conry RM. Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen. Gene Ther. 5(7), 865–868 (1998).
  • Yu WY, Chuang TF, Guichard C et al. Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model. Vaccine 29(18), 3489–3500 (2011).
  • Pai CC, Kuo TF, Mao SJ, Chuang TF, Lin CS, Chu RM. Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid. Vet. Immunol. Immunopathol. 139(2–4), 187–199 (2011).
  • Murchison EP. Clonally transmissible cancers in dogs and Tasmanian devils. Oncogene 27(Suppl. 2), S19–S30 (2008).
  • van Drunen Littel-van den H, Babiuk SL, Babiuk LA. Strategies for improved formulation and delivery of DNA vaccines to veterinary target species. Immunol. Rev. 199, 113–125 (2004).
  • Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ. Comparison of error rates in single-arm versus randomized Phase II cancer clinical trials. J. Clin. Oncol. 28(11), 1936–1941 (2010).
  • Sharma MR, Stadler WM, Ratain MJ. Randomized Phase II trials: a long-term investment with promising returns. J. Natl Cancer Inst. 103(14), 1093–1100 (2011).
  • Farley J, Rose PG. Trial design for evaluation of novel targeted therapies. Gynecol. Oncol. 116(2), 173–176 (2010).
  • Bergman PJ, Camps-Palau MA, McKnight JA et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24(21), 4582–4585 (2006).
  • Bergman PJ, McKnight J, Novosad A et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a Phase I trial. Clin. Cancer Res. 9(4), 1284–1290 (2003).
  • Manley CA, Leibman NF, Wolchok JD et al. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. J. Vet. Intern. Med. 25(1), 94–99 (2011).
  • Liao JC, Gregor P, Wolchok JD et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun. 6, 8 (2006).
  • Michaeli Y, Denkberg G, Sinik K et al. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. J. Immunol. 182(10), 6328–6341 (2009).
  • Benjamini E, Theilen GH, Torten M, Fong S, Crow S, Henness AM. Tumor vaccines for immunotherapy of canine lymphosarcoma. Ann. NY Acad. Sci. 277(00), 305–312 (1976).
  • Argyle DJ, Nasir L. Telomerase: a potential diagnostic and therapeutic tool in canine oncology. Vet. Pathol. 40(1), 1–7 (2003).
  • Kow K, Thamm DH, Terry J et al. Impact of telomerase status on canine osteosarcoma patients. J. Vet. Intern. Med. 22(6), 1366–1372 (2008).
  • Long S, Argyle DJ, Nixon C et al. Telomerase reverse transcriptase (TERT) expression and proliferation in canine brain tumours. Neuropathol. Appl. Neurobiol. 32(6), 662–673 (2006).
  • Mandrioli L, Panarese S, Cesari A, Mandara MT, Marcato PS, Bettini G. Immunohistochemical expression of h-telomerase reverse transcriptase in canine and feline meningiomas. J. Vet. Sci. 8(2), 111–115 (2007).
  • U’Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J. Vet. Intern. Med. 21(1), 113–120 (2007).
  • Jeglum KA, Young KM, Barnsley K, Whereat A, McGrath D, Hutson C. Intralymphatic autochthonous tumor cell vaccine in canine lymphoma. J. Biol. Response Mod. 5(2), 168–175 (1986).
  • Jeglum KA, Young KM, Barnsley K, Whereat A. Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma. Cancer 61(10), 2042–2050 (1988).
  • Mason NJ, Coughlin CM, Overley B et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther. 15(13), 955–965 (2008).
  • Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J. Comput. Assist. Tomogr. 34(4), 479–484 (2010).
  • Mackiewicz J, Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. Eur. J. Pharmacol. 625(1-3), 84–89 (2009).
  • Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur. J. Cancer 46(9), 1514–1519 (2010).
  • Hogge GS, Burkholder JK, Culp J et al. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum. Gene Ther. 9(13), 1851–1861 (1998).
  • Chauvet AE, Hogge GS, Sandin JA, Lipsitz D. Vertebrectomy, bone allograft fusion, and antitumor vaccination for the treatment of vertebral fibrosarcoma in a dog. Vet. Surg. 28(6), 480–488 (1999).
  • Alexander AN, Huelsmeyer MK, Mitzey A et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a Phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol. Immunother. 55(4), 433–442 (2006).
  • Kamstock D, Elmslie R, Thamm D, Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol. Immunother. 56(8), 1299–1309 (2007).
  • Lawman M, Eidizadeh S, Selmon C et al. Anti-tumor response induced by autologous cancer vaccine in canine lymphoma. Cancer Therapy 6, 827–840 (2008).
  • Pluhar GE, Grogan PT, Seiler C et al. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 28(19), 3371–3378 (2010).
  • Rossi A, Maione P, Schettino C et al. Non-small-cell lung carcinoma vaccines in clinical trials. Expert Rev. Vaccines 10(6), 887–897 (2011).
  • Leffers N, Daemen T, Boezen HM, Melief KJ, Nijman HW. Vaccine-based clinical trials in ovarian cancer. Expert Rev. Vaccines 10(6), 775–784 (2011).
  • Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Rev. Vaccines 10(6), 755–774 (2011).
  • Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev. Vaccines 10(6), 743–753 (2011).
  • Rezvani K, de Lavallade H. Vaccination strategies in lymphomas and leukaemias: recent progress. Drugs 71(13), 1659–1674 (2011).
  • Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ, van der Burg SH. Colorectal cancer vaccines in clinical trials. Expert Rev. Vaccines 10(6), 899–921 (2011).
  • Klein O, Schmidt C, Knights A, Davis ID, Chen W, Cebon J. Melanoma vaccines: developments over the past 10 years. Expert Rev. Vaccines 10(6), 853–873 (2011).
  • Brookman-May S, Burger M, Wieland WF, Rössler W, May M, Denzinger S. Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev. Vaccines 10(6), 837–852 (2011).
  • Plate J. Clinical trials of vaccines for immunotherapy in pancreatic cancer. Expert Rev. Vaccines 10(6), 825–836 (2011).
  • Bridle BW. Neuroendocrine cancer vaccines in clinical trials. Expert Rev. Vaccines 10(6), 811–823 (2011).
  • Ebben JD, Rocque BG, Kuo JS. Tumour vaccine approaches for CNS malignancies: progress to date. Drugs 69(3), 241–249 (2009).
  • Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9(10), 776–788 (2008).
  • Janetzki S, Britten CM, Kalos M et al. “MIATA”-minimal information about T cell assays. Immunity 31(4), 527–528 (2009).
  • Bergman PJ, Wolchok JD. Of mice and men (and dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma. Cancer Therapy 6, 817–826 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.